Asep Medical Holdings Inc. $ASEP $ASEP.C has finalized an exclusive licensing arrangement with the University of British Columbia for a patented and potentially groundbreaking AI-driven technology that enables early and accurate diagnosis of sepsis, which is also a major contributing factor in COVID-19 morbidity.
$ASEP’s novel diagnostic test called SepsetER senses the dysfunctional immune response underlying sepsis at the time that patients first enter the emergency room. The test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. Current diagnostic tools deliver results after approximately 24-36 hours often delaying the initiation of treatment.
SepsetER is designed to enable physicians to quickly predict the severity of the disease and thus define better, more immediate treatment options for the patient.
The global market for sepsis diagnosis is expected to reach USD $771-$975 million by 2026, representing a massive growth opportunity for this pre-revenue company. Its technology will provide the medical industry with a huge advantage over all current technologies used in the diagnosis of the disease, potentially saving millions of lives.
$ASEP is currently trading at $.35 and the company is valued at an MCAP of $19.65 million.
https://ceo.ca/@newswire/asep-medical-holdings-inc-announces-an-exclusive-licensing